Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Acerus Pharmaceuticals Corporation
  6. News
  7. Summary
    ASP   CA00444G1081

ACERUS PHARMACEUTICALS CORPORATION

(ASP)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Acerus Provides Update on Litigation with Recipharm

07/12/2021 | 07:31am EDT

TORONTO, July 12, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that, on June 15, 2021, it prevailed at a preliminary issue trial in which Recipharm Limited (“Recipharm”) alleged that Acerus’ claim for damages was barred by the terms of the companies’ manufacturing contract. In agreeing with Acerus that its claim for damages was not barred, the Commercial Court of London directed the matter to proceed to a full trial in the coming months. Recipharm has asked for permission to appeal the court’s decision.

"This is an important step forward in Acerus’ effort to hold Recipharm accountable for its contractual breaches,” said Ed Gudaitis, President and Chief Executive Officer of Acerus. “Manufacturers in the pharmaceutical industry rely on contract manufacturing organizations like Recipharm to ensure that patients have access to the medicines they need. We are pleased with the court’s decision and are confident that the appeal process will resolve this issue in our favor."

On June 18, 2020, Acerus announced it had commenced litigation against Recipharm, a wholly-owned subsidiary of Recipharm AB, in the Commercial Court of London. Acerus alleged that the suspension of Recipharm’s manufacturing license in August 2018 was a violation of its contractual obligations and led to a shortage of Estrace® in Canada.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the potential success of the litigation proceedings against Recipharm, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 10, 2021 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Media contact:

Chris Witty
Acerus Investor Relations
(646) 438-9385
cwitty@darrowir.com


Primary Logo


© GlobeNewswire 2021
All news about ACERUS PHARMACEUTICALS CORPORATION
08/23Acerus Announces Participation in HC Wainwright Conference
GL
08/12ACERUS PHARMACEUTICALS : Reports Acceptance of Part 36 Settlement Offer in Recipharm Litig..
MT
08/12Acerus Reports Acceptance of Part 36 Settlement Offer in Recipharm Litigation
GL
08/10ACERUS PHARMACEUTICALS : Q2 EPS US$0.00 Vs Loss $0.01 a Year Ago; Provides Update and Outl..
MT
08/10Acerus Reports Fiscal 2021 Second Quarter Financial Results
GL
08/09ACERUS : Q2 Earnings Snapshot
AQ
08/09Acerus Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter Ende..
CI
08/03Acerus to Report Q2-2021 Financial Results and Host Investor Call
GL
07/12ACERUS PHARMACEUTICALS : Says Legal Battle with Manufacturing Partner Recipharm Headed to ..
MT
07/12Acerus Provides Update on Litigation with Recipharm
GL
More news
Financials (USD)
Sales 2020 1,09 M - -
Net income 2020 -24,4 M - -
Net cash 2020 0,91 M - -
P/E ratio 2020 -1,05x
Yield 2020 -
Capitalization 49,7 M 49,7 M -
EV / Sales 2019 8,18x
EV / Sales 2020 43,7x
Nbr of Employees 10
Free-Float 8,63%
Chart ACERUS PHARMACEUTICALS CORPORATION
Duration : Period :
Acerus Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACERUS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Managers and Directors
Edward Gudaitis President, CEO & Non-Independent Director
Robert M. Motz Chief Financial Officer
Ian Orest Ihnatowycz Chairman
Christopher Sorli Chief Medical Officer
Stephen Robert Gregory Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ACERUS PHARMACEUTICALS CORPORATION0.00%50
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY44.37%220 979